Fred M. Teskin

Array ( [id] => 18117560 [patent_doc_number] => 11548941 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-10 [patent_title] => Safe and effective method of treating psoriasis with anti-IL-23 specific antibody [patent_app_type] => utility [patent_app_number] => 16/688178 [patent_app_country] => US [patent_app_date] => 2019-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 13 [patent_no_of_words] => 40894 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16688178 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17541025 [patent_doc_number] => 11306136 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-19 [patent_title] => Selective IL-6-trans-signalling inhibitor compositions [patent_app_type] => utility [patent_app_number] => 16/675621 [patent_app_country] => US [patent_app_date] => 2019-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 8233 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16675621 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17252220 [patent_doc_number] => 11187704 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => IL-6 signaling and breast cancer [patent_app_type] => utility [patent_app_number] => 16/660524 [patent_app_country] => US [patent_app_date] => 2019-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 22 [patent_no_of_words] => 17980 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16660524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15454517 [patent_doc_number] => 20200040083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => IL15/IL15Ralpha HETERODIMERIC Fc-FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 16/660028 [patent_app_country] => US [patent_app_date] => 2019-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33733 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16660028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17997856 [patent_doc_number] => 11498950 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-11-15 [patent_title] => Fusion molecules and IL-15 variants [patent_app_type] => utility [patent_app_number] => 16/659311 [patent_app_country] => US [patent_app_date] => 2019-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 50 [patent_no_of_words] => 26828 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16659311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866219 [patent_doc_number] => 20200140513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => FUSION MOLECULES AND IL-15 VARIANTS [patent_app_type] => utility [patent_app_number] => 16/654958 [patent_app_country] => US [patent_app_date] => 2019-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16654958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17467688 [patent_doc_number] => 11274156 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-15 [patent_title] => Compositions and methods for targeted immunomodulatory antibodies and fusion proteins [patent_app_type] => utility [patent_app_number] => 16/601347 [patent_app_country] => US [patent_app_date] => 2019-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 75 [patent_figures_cnt] => 90 [patent_no_of_words] => 23571 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16601347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866217 [patent_doc_number] => 20200140512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => PD-1 TARGETED IL-15/IL-15RALPHA FC FUSION PROTEINS AND USES IN COMBINATION THERAPIES THEREOF [patent_app_type] => utility [patent_app_number] => 16/600236 [patent_app_country] => US [patent_app_date] => 2019-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47069 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16600236 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283766 [patent_doc_number] => 20200277368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => Methods for Treating Psoriasis Using an Anti-IL-23 Antibody [patent_app_type] => utility [patent_app_number] => 16/598714 [patent_app_country] => US [patent_app_date] => 2019-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9093 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16598714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15678515 [patent_doc_number] => 20200093921 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRP [patent_app_type] => utility [patent_app_number] => 16/591668 [patent_app_country] => US [patent_app_date] => 2019-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 120027 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16591668 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15586393 [patent_doc_number] => 20200069731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => METHODS AND COMPOSITIONS OF TREATING AUTOIMMUNE DISEASES [patent_app_type] => utility [patent_app_number] => 16/588234 [patent_app_country] => US [patent_app_date] => 2019-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16588234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15649731 [patent_doc_number] => 20200087395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => CD200R AGONIST ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/567256 [patent_app_country] => US [patent_app_date] => 2019-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12213 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16567256 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17756256 [patent_doc_number] => 11396540 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-07-26 [patent_title] => Methods for making recombinant proteins [patent_app_type] => utility [patent_app_number] => 16/564642 [patent_app_country] => US [patent_app_date] => 2019-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 29 [patent_no_of_words] => 37043 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16564642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18215309 [patent_doc_number] => 11590223 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-28 [patent_title] => Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies [patent_app_type] => utility [patent_app_number] => 16/556885 [patent_app_country] => US [patent_app_date] => 2019-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 29112 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 361 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16556885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711259 [patent_doc_number] => 20200102395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS [patent_app_type] => utility [patent_app_number] => 16/553338 [patent_app_country] => US [patent_app_date] => 2019-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37331 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16553338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206576 [patent_doc_number] => 20200239566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => ANTI-TLR4 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/541676 [patent_app_country] => US [patent_app_date] => 2019-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11280 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16541676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15345301 [patent_doc_number] => 20200010542 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => ANTIBODIES FOR IL-17C [patent_app_type] => utility [patent_app_number] => 16/531462 [patent_app_country] => US [patent_app_date] => 2019-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24755 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16531462 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15410909 [patent_doc_number] => 20200025776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody [patent_app_type] => utility [patent_app_number] => 16/515433 [patent_app_country] => US [patent_app_date] => 2019-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31035 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16515433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17206653 [patent_doc_number] => 11167004 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-09 [patent_title] => Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor [patent_app_type] => utility [patent_app_number] => 16/513285 [patent_app_country] => US [patent_app_date] => 2019-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28348 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 168 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16513285 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17769400 [patent_doc_number] => 11401328 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => Antibodies binding to ILT4 [patent_app_type] => utility [patent_app_number] => 16/506754 [patent_app_country] => US [patent_app_date] => 2019-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 69 [patent_no_of_words] => 51971 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16506754 [rel_patent_id] =>[rel_patent_doc_number] =>)